by Madaline Spencer and Peter Ciszewski | Jul 4, 2023
Kim Moran, Ph.D., MBA, Head of US Rare Diseases at UCB, discusses the two orphan drugs, rozanolixizumab and zilucoplan, which the company hopes to have approved shortly to treat myasthenia gravis. Myasthenia gravis is a rare autoimmune disorder that targets the...
by Madaline Spencer and James Radke, PhD | Jun 29, 2023
Nicholas E. Johnson, MD, Associate Professor in the Department of Neurology at Virginia Commonwealth University, summarizes data from the phase 1/2 MARINA trial. This trial tested AOC 1001 in patients with myotonic dystrophy type 1 (DM1). DM1 is a progressive...
by Peter Ciszewski | Jun 28, 2023
Nicholas Johnson, MD, Associate Professor in the Department of Neurology at Virginia Commonwealth University, explains myotonic dystrophy type 1 and how it is currently managed. DM1 is a progressive neuromuscular disease caused by a triple repeat in the DMPK...
by CheckRare Staff | Jun 27, 2023
Milan Radovich, Ph.D., Chief Scientific Officer at Caris Life Sciences, summarizes the company’s comprehensive clinico-genomic database being used to advance targeted therapy for various cancer types. As noted by Dr. Radovich, Caris performed whole...
by CheckRare Staff | Jun 26, 2023
Chadi Nabhan, MD, of Caris Life Sciences, summarizes the Caris Precision Oncology Alliance and some of the abstracts the alliance presented at ASCO 2023. The Precision Oncology Alliance includes partnerships with 83 cancer centers and academic...
